References
- American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society, 2011. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2011. Accessed June 14, 2015
- Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2012. Eur J Cancer 2012;48:2375-90
- Cancer research UK. Melanoma skin cancer. 2015. http://www.cancerresearchuk.org/about-cancer/type/melanoma/treatment/melanoma-statistics-and-outlook. Accessed May 14, 2015
- Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84
- EMA. European Public Assessment Report for Yervoy (ipilimumab). London: EMA, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002213/WC500157027.pdf. Accessed April 28, 2015
- Song X, Zhao Z, Barber B, et al. Overall survival in patients with metastatic melanoma. Curr Med Res Opin 2015;31:987-91
- Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
- International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon: International Agency for Research on Cancer, 2013. http://www.iarc.fr/. Accessed May 20, 2015
- Ekwueme DU, Guy GP, Jr., Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol 2011;65(5 Suppl 1):S133-43
- Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer 2015;136:E136-45.
- Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. Dermatol Online J 2009;15:1
- Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-medicare linked database. Appl Health Econ Health Policy 2009;7:31-41
- Marzuka A, Huang L, Theodosakis N, et al. Melanoma treatments: advances and mechanisms. J Cell Physiol 2015;230:2326-33
- Wisdom J, Creswell JW. Mixed methods: integrating quantitative and qualitative data collection and analysis while studying patient-centered medical home models. Rockville, MD: Agency for Healthcare Research and Quality, 2013. https://pcmh.ahrq.gov/sites/default/files/attachments/MixedMethods_032513comp.pdf. Accessed October 13, 2015
- Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(7 Suppl):vii86-91
- Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:395-407
- AIOM. Linee guida melanoma. 2013. http://www.aiom.it/C_Common/Download.asp?file=/$Site$/Attivita_Scientifica/Linee_Guida/2013/Melanoma_v6_24.09.13.pdf. Accessed June 14, 2015
- Alberta Health Services. Systemic therapy for unresectable stage III or metastatic cutaneous melona, version 2. 2013. http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-cu012-systemic-therapy.pdf. Accessed June 14, 2015
- British Columbia Cancer Agency. Melonama guideline, recurrent and/or metastatic disease. 2013. http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/skin/melanoma#Recurrent-and-or-Metastatic-Disease. Accessed October 13, 2015
- Cancer Care Ontario. Systemic Adjuvant Therapy for patients at high risk for recurrent melanoma, Toronto: Cancer Care Ontario, 2013. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34373. Accessed October 13, 2015
- IKNL. Melanoom, Landelijke richtlijn, Versie: 2.0. 2012. http://www.oncoline.nl/melanoom. Accessed October 13, 2015
- Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg 2010;63:1401-19
- NHMRC, Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. 2008. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp111.pdf. Accessed October 13, 2015
- SEOM. Melanoma Madrid: SEOM, 2013. http://www.seom.org/en/informacion-sobre-el-cancer/info-tipos-cancer/melanoma. Accessed October 13, 2015
- Bedane C, Leccia MT, Sassolas B, et al. Treatment patterns and outcomes in patients with advanced melanoma in France. Curr Med Res Opin 2013;29:1297-305
- Johnston K, Levy AR, Lorigan P, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48:2175-82
- Lebbe C, Lorigan P, Ascierto P, et al. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). Eur J Cancer 2012;48:3205-14
- Lorigan P, Marples M, Harries M, et al. Treatment patterns, outcomes, and resource utilisation of patients with metastatic melanoma in the UK: the MELODY study. Br J Dermatol 2014;170:87-95
- Maio M, Ascierto P, Testori A, et al. The cost of unresectable stage III or stage IV melanoma in Italy. J Exp Clin Cancer Res 2012;31:91
- NICE, Liverpool Reviews and Implementation Group. Ipilimumab for previously treated unresectable malignant melanoma Liverpool: NICE, 2011. https://www.nice.org.uk/guidance/ta268/documents/melanoma-stage-iii-or-iv-ipilimumab-evidence-review-group-report3. Accessed April 28, 2015
- Asseburg C, Frank M, Kohne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33:482-97
- Isla D, Gonzalez-Rojas N, Nieves D, et al. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011;13:460-71
- Kim K, Hernlund E, Hernadi Z, et al. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. Int J Gynecol Cancer 2013;23:823-32
- Lee D, Gladwell D, Batty AJ, et al. The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited. Paediatr Drugs 2013;15:151-62
- NICE. Methods guide: assessing cost impact. London: NICE, 2011. http://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/Costing_Manual_update_050811.pdf. Accessed April 28, 2015
- Gordon TJ. The delphi method. In Future Res Methodol version 3.0. Eds. Glenn JC, Gordon TJ. Washington DC, 2009.
- Hsu C, Sandford B. The Delphi technique: making sense of consensus. Pract Assess Res Eval 2007;12:1-8
- Van Zolingen SJ, Klaassen CA. Selection processes in a Delphi study about key qualifications in Senior Secondary Vocational Education. Technol Forecast Soc Change 2003;70:317-40
- Addicott R, Dewar S. Improving choice at end of life: a descriptive analysis of the impact and costs of the Marie Curie delivering choice programme in Lincolnshire. London: King's Fund, 2008. http://www.kingsfund.org.uk/sites/files/kf/improving-choice-end-of-life-descriptive-analysis-impact-costs-marie-curie-choice-programme-lincolnshire-rachael-addicot-steve-dewar-april-2008.pdf. Accessed October 13, 2015
- NCCN. Clinical practice guidelines in oncology: melanoma. Version 2. Fort Washington PA: NCCN, 2013. www.nccn.com. Accessed September 30, 2013
- Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180-6
- Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522-9
- Farr AM, Zhao Z, Song X, et al. Medical Costs by disease stage in Medicare patients with melanoma. Value Health 2014;3:A78